Official Title: N-acetyl-L-cysteine for Promoting Hematopoietic Recovery in Patients With Severe Aplastic Anemia SAA After Haploidentical Transplantation -- a Prospective Single-arm Clinical Study
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a prospective single-arm clinical study to evaluate the role of NAC among patients with severe aplastic anemia SAA can promote hematopoietic recovery after haploidentical transplantation
Detailed Description: Allogeneic hematopoietic stem cell transplantation allo-HSCT is an effective treatment of severe aplastic anemia SAA However poor hematopoietic reconstitution including poor graft function PGF and prolonged isolated thrombocytopenia PT remains a life-threatening complication after allo-HSCT Especially with the increasing use of haploidentical allo-HSCT haplo-HSCT in the past ten years PGF and PT have become growing obstacles contributing to high morbidity and mortality after allo-HSCT A previous clinical prospective cohort study showed that NAC could improve the function of bone marrow endothelial progenitor cells and promote hematopoietic recovery among leukemia patients after haploidentical transplantation Therefore we hypothesized that the prophylactic administration of NAC could facilitate the recovery of hematopoietic capacity by improving the bone marrow microenvironment of patients with SAA after haploidentical transplantation